| Dr Manoochehr Abadian Sharifabad, MD | |
|
17100 Euclid St, Fountain Valley, CA 92708-4004 | |
| (714) 241-8552 | |
| (714) 241-8551 |
| Full Name | Dr Manoochehr Abadian Sharifabad |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 23 Years |
| Location | 17100 Euclid St, Fountain Valley, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164655817 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 4301099978 (Michigan) | Primary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | A107180 (California) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fountain Valley Regional Hospital & Medical Center | Fountain valley, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| First Choice Physician Partners | 0941465322 | 207 |
News Archive
Researchers at the University of Gothenburg, Sweden, have developed new methods for analysing medical databases that can be used to identify diagnostic markers more quickly and to personalise medication for allergic disorders. They could also reduce the need for animal trials in clinical studies.
Every aging baby boomer listens for the footsteps of Alzheimer's, and for good reason: It's estimated that 10 million American boomers will develop the disease. The need to develop preventative strategies, ideally long before Alzheimer's destructive, clinical symptoms appear, is critical.
Writing in the December 30, 2019 online issue of Neurology, researchers at University of California San Diego School of Medicine and Veterans Affairs San Diego Healthcare System report that accumulating amyloid - an abnormal protein linked to neurodegenerative conditions such as Alzheimer's disease - occurred faster among persons deemed to have "objectively-defined subtle cognitive difficulties" (Obj-SCD) than among persons considered to be "cognitively normal."
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data from AVEO's anti-RON antibody program which demonstrated the successful identification of antibodies with potent anti-tumor activity that demonstrated inhibition of the function of both wild type RON and the RONΔ160 variant, as well as a potential biomarker to identify tumors likely to respond to treatment with the anti-RON antibody.
› Verified 5 days ago
| Entity Name | First Choice Physician Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104183052 PECOS PAC ID: 0941465322 Enrollment ID: O20120710000480 |
News Archive
Researchers at the University of Gothenburg, Sweden, have developed new methods for analysing medical databases that can be used to identify diagnostic markers more quickly and to personalise medication for allergic disorders. They could also reduce the need for animal trials in clinical studies.
Every aging baby boomer listens for the footsteps of Alzheimer's, and for good reason: It's estimated that 10 million American boomers will develop the disease. The need to develop preventative strategies, ideally long before Alzheimer's destructive, clinical symptoms appear, is critical.
Writing in the December 30, 2019 online issue of Neurology, researchers at University of California San Diego School of Medicine and Veterans Affairs San Diego Healthcare System report that accumulating amyloid - an abnormal protein linked to neurodegenerative conditions such as Alzheimer's disease - occurred faster among persons deemed to have "objectively-defined subtle cognitive difficulties" (Obj-SCD) than among persons considered to be "cognitively normal."
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data from AVEO's anti-RON antibody program which demonstrated the successful identification of antibodies with potent anti-tumor activity that demonstrated inhibition of the function of both wild type RON and the RONΔ160 variant, as well as a potential biomarker to identify tumors likely to respond to treatment with the anti-RON antibody.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Manoochehr Abadian Sharifabad, MD 17100 Euclid St, Fountain Valley, CA 92708-4004 Ph: (714) 241-8552 | Dr Manoochehr Abadian Sharifabad, MD 17100 Euclid St, Fountain Valley, CA 92708-4004 Ph: (714) 241-8552 |
News Archive
Researchers at the University of Gothenburg, Sweden, have developed new methods for analysing medical databases that can be used to identify diagnostic markers more quickly and to personalise medication for allergic disorders. They could also reduce the need for animal trials in clinical studies.
Every aging baby boomer listens for the footsteps of Alzheimer's, and for good reason: It's estimated that 10 million American boomers will develop the disease. The need to develop preventative strategies, ideally long before Alzheimer's destructive, clinical symptoms appear, is critical.
Writing in the December 30, 2019 online issue of Neurology, researchers at University of California San Diego School of Medicine and Veterans Affairs San Diego Healthcare System report that accumulating amyloid - an abnormal protein linked to neurodegenerative conditions such as Alzheimer's disease - occurred faster among persons deemed to have "objectively-defined subtle cognitive difficulties" (Obj-SCD) than among persons considered to be "cognitively normal."
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data from AVEO's anti-RON antibody program which demonstrated the successful identification of antibodies with potent anti-tumor activity that demonstrated inhibition of the function of both wild type RON and the RONΔ160 variant, as well as a potential biomarker to identify tumors likely to respond to treatment with the anti-RON antibody.
› Verified 5 days ago
Dr. Kristine Suzanne Olson Arthur, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 11420 Warner Ave, Fountain Valley, CA 92708 Phone: 714-549-1300 Fax: 714-433-3100 | |
Dr. Sajeet Singh Sawhney, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 11100 Warner Ave, Suite 218, Fountain Valley, CA 92708 Phone: 714-641-9696 Fax: 714-641-9696 | |
Dr. Jennifer L Wong, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 18111 Brookhurst St Ste 5100, Fountain Valley, CA 92708 Phone: 714-546-2238 Fax: 714-434-8145 | |
Dr. Sithu Lin, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 11100 Warner Ave Ste 218, Fountain Valley, CA 92708 Phone: 714-641-9696 | |
Kien-an Duong, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 11420 Warner Ave, Fountain Valley, CA 92708 Phone: 714-549-1300 Fax: 714-433-3100 | |
Mr. Satinder Swaroop, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 11180 Warner Ave, Suite #353, Fountain Valley, CA 92708 Phone: 714-751-3540 Fax: 714-751-5626 | |
Yu-ming Ni, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 18111 Brookhurst St Ste 5100, Fountain Valley, CA 92708 Phone: 714-546-2238 |